Dr. Xinfeng Zhang 张鑫丰
Chief Physician
Department of Breast Surgery, Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and differential diagnosis of benign and malignant breast tumors. Modified radical mastectomy, breast-conserving surgery, and minimally invasive procedures for benign tumors. Comprehensive treatment of malignant breast tumors with attention to postoperative survival quality.
Dr. Zhang is Deputy Director of Ward 1, Department of Breast Surgery, Liaoning Cancer Hospital & Institute. Holding a medical doctorate from China Medical University, Dr. Zhang has nearly 15 years of clinical experience. In 2012, Dr. Zhang was a visiting scholar at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. From 2018 to 2020, Dr. Zhang conducted medical exchanges at the University of California, Los Angeles, and Cedars-Sinai Medical Center.
Professional roles
- Member, Breast Tumor Group, Chinese Medical Association
- Member, Youth Committee, Breast Cancer Professional Committee, China Anti-Cancer Association
- Member, Shenyang Study Group, Breast Branch, China Medicine Education Association
- Member, Youth Committee, China Maternal and Child Health Care Association
Name order: in Chinese the family name comes first (Zhang Xinfeng). Papers usually list the name as Xinfeng Zhang or Zhang X.
Selected publications
12 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Pharmaceutics, 2024 (senior author): Nanotheranostics in Breast Cancer Bone Metastasis: Advanced Research Progress and Future Perspectives. PubMed 39771471
- Front Bioeng Biotechnol, 2024 (senior author): Nanotechnology for the theranostic opportunity of breast cancer lung metastasis: recent advancements and future challenges. PubMed 38882636
- J Magn Reson Imaging, 2023 (senior author): Serial Cardiac MRI for Quantification of the Dynamics of Anthracycline-Induced Subclinical Myocardial Injury. PubMed 36912379
- Arch Med Sci, 2023 (senior author): MicroRNA-325 targets lipocalin 15 to suppress proliferation, migration and invasion of breast cancer cells. PubMed 37560715
- Quant Imaging Med Surg, 2020 (first author): The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer. PubMed 31956542
- Int J Clin Exp Pathol, 2015 (first author): Overexpression of long non-coding RNA CCAT1 is a novel biomarker of poor prognosis in patients with breast cancer. PubMed 26464701
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion